A. Erik G. Persson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. Erik G. Persson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
En Yin Lai
Uppsala Univ, Ctr Biomed, Dept Med Cell Biol, Div Physiol, S-75123 Uppsala, Sweden
2 shared publications- Lina Nordquist
Department of Medical Cell Biology, Division of Integrative Physiology, Uppsala University, Uppsala, Sweden
2 shared publications Mats Sjöquist
Uppsala Univ, Ctr Biomed, Dept Med Cell Biol, Div Physiol, S-75123 Uppsala, Sweden
2 shared publicationsA. Ollerstam
Department of Physiology, Uppsala University, Sweden
1 shared publication- Andreas Patzak
Institute of Translational Physiology Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
1 shared publication - Bertil B. Fredholm
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 August 2015
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 6, 222
In adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver
Rationale: Accumulating studies suggest that nitric oxide (NO) deficiency and oxidative stress are central pathological mechanisms in type 2 diabetes. Recent findings demonstrate therapeutic effects by boosting a nitrate-nitrite-NO pathway, an alternative pathway for NO formation. This study aimed at investigating the acute effects of inorganic nitrate on glucose and insulin signaling in adenosine A2B receptor knockout mice (A2B-/-), a genetic model of impaired metabolic regulation. Methods: Acute effects of nitrate treatment were investigated in aged wild-type (WT) and A2B-/- mice. One hour after injection with nitrate or placebo, metabolic regulation was evaluated by glucose and insulin tolerance tests. NADPH oxidase-mediated superoxide production and AMPK phosphorylation were measured in livers obtained from non-treated or glucose-treated mice, with or without prior nitrate injection. Plasma was used to determine insulin resistance (HOMA-IR) and NO signaling. Results: A2B-/- displayed increased body weight, reduced glucose clearance and attenuated overall insulin responses compared with age-matched WT. Nitrate treatment increased circulating levels of nitrate, nitrite and cGMP in A2B-/-, and improved glucose clearance. In WT mice, however, nitrate treatment did not influence glucose clearance. HOMA-IR increased following glucose injection in A2B-/-, but remained at basal levels in mice pretreated with nitrate. NADPH oxidase activity in livers from A2B-/-, but not WT mice, was reduced by nitrate. Livers from A2B-/- displayed reduced AMPK phosphorylation compared with WT mice, and this was increased by nitrate treatment. Injection with the anti-diabetic agent metformin induced similar therapeutic effects in the A2B-/- as observed with nitrate. Conclusion: The A2B-/- mouse is a genetic model of metabolic syndrome. Acute treatment with nitrate improved the metabolic profile, at least partly via reduction in oxidative stress and improved AMPK signaling in the liver.
- 7 August 2015
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 6, 222
Open AccessIn adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver
Rationale: Accumulating studies suggest that nitric oxide (NO) deficiency and oxidative stress are central pathological mechanisms in type 2 diabetes. Recent findings demonstrate therapeutic effects by boosting a nitrate-nitrite-NO pathway, an alternative pathway for NO formation. This study aimed at investigating the acute effects of inorganic nitrate on glucose and insulin signaling in adenosine A2B receptor knockout mice (A2B-/-), a genetic model of impaired metabolic regulation. Methods: Acute effects of nitrate treatment were investigated in aged wild-type (WT) and A2B-/- mice. One hour after injection with nitrate or placebo, metabolic regulation was evaluated by glucose and insulin tolerance tests. NADPH oxidase-mediated superoxide production and AMPK phosphorylation were measured in livers obtained from non-treated or glucose-treated mice, with or without prior nitrate injection. Plasma was used to determine insulin resistance (HOMA-IR) and NO signaling. Results: A2B-/- displayed increased body weight, reduced glucose clearance and attenuated overall insulin responses compared with age-matched WT. Nitrate treatment increased circulating levels of nitrate, nitrite and cGMP in A2B-/-, and improved glucose clearance. In WT mice, however, nitrate treatment did not influence glucose clearance. HOMA-IR increased following glucose injection in A2B-/-, but remained at basal levels in mice pretreated with nitrate. NADPH oxidase activity in livers from A2B-/-, but not WT mice, was reduced by nitrate. Livers from A2B-/- displayed reduced AMPK phosphorylation compared with WT mice, and this was increased by nitrate treatment. Injection with the anti-diabetic agent metformin induced similar therapeutic effects in the A2B-/- as observed with nitrate. Conclusion: The A2B-/- mouse is a genetic model of metabolic syndrome. Acute treatment with nitrate improved the metabolic profile, at least partly via reduction in oxidative stress and improved AMPK signaling in the liver.
- Open Access
- 13 September 2013
- Published by Taylor & Francis in Islets
- Vol. 5 (5) , 201-206
Short-term glucosamine infusion increases islet blood flow in anesthetized rats
Impaired glucose tolerance and type 2 diabetes in rodents are associated with increased islet blood flow. If this is important for modulation of the endocrine function is at present unknown. We evaluated if glucosamine infusion, which induces peripheral insulin resistance and glucose intolerance, could be used to acutely increase islet blood flow. We infused anaesthetized Sprague-Dawley rats for 2 h with glucosamine (6 mg/kg body weight), in some cases followed by glucose administration. The former induced a 2-fold increase in serum insulin concentrations while plasma glucose remained unchanged. In vitro an augmented insulin response to hyperglycemia and decreased insulin content in batch type islet incubations with glucosamine for 24 h were seen. After 2 h glucosamine exposure in vitro, insulin release was decreased. In vivo glucosamine infusion increased islet blood flow, without affecting other regional blood flow values. Glucose increased islet blood flow to the same extent in control and glucosamine-infused rats. When exposed to 10 mmol/L glucosamine arterioles of isolated perfused islets showed a 10% dilation of their vascular smooth muscle. Thus, application of this model leads to acute hyperinsulinemia in vivo but a decreased insulin release in vitro, which suggests that effects not located to β cells are responsible for the effects seen in vivo. An increased islet blood flow in previously healthy animals was also seen after glucose administration, which can be used to further dissect the importance of blood flow changes in islet function.
- 13 September 2013
- Published by Taylor & Francis in Islets
- Vol. 5 (5) , 201-206
Open AccessShort-term glucosamine infusion increases islet blood flow in anesthetized rats
Impaired glucose tolerance and type 2 diabetes in rodents are associated with increased islet blood flow. If this is important for modulation of the endocrine function is at present unknown. We evaluated if glucosamine infusion, which induces peripheral insulin resistance and glucose intolerance, could be used to acutely increase islet blood flow. We infused anaesthetized Sprague-Dawley rats for 2 h with glucosamine (6 mg/kg body weight), in some cases followed by glucose administration. The former induced a 2-fold increase in serum insulin concentrations while plasma glucose remained unchanged. In vitro an augmented insulin response to hyperglycemia and decreased insulin content in batch type islet incubations with glucosamine for 24 h were seen. After 2 h glucosamine exposure in vitro, insulin release was decreased. In vivo glucosamine infusion increased islet blood flow, without affecting other regional blood flow values. Glucose increased islet blood flow to the same extent in control and glucosamine-infused rats. When exposed to 10 mmol/L glucosamine arterioles of isolated perfused islets showed a 10% dilation of their vascular smooth muscle. Thus, application of this model leads to acute hyperinsulinemia in vivo but a decreased insulin release in vitro, which suggests that effects not located to β cells are responsible for the effects seen in vivo. An increased islet blood flow in previously healthy animals was also seen after glucose administration, which can be used to further dissect the importance of blood flow changes in islet function.
- Open Access
- 1 March 2008
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 294 (3) , R836-R841
Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism
Objective : an increased glomerular filtration rate (GFR) has been postulated as a potential mechanism involved in the progression of diabetic nephropathy. Studies suggest that C-peptide exerts a renoprotective effect on diabetes. The peptide decreases hyperfiltration in patients with type 1 diabetes, as well as in diabetic animal models. In this study, we investigated whether C-peptide causes a change in arteriolar diameter. Research Design and Methods : C57-Bl mice were made diabetic by means of a single intravenous injection of alloxan 2 wk prior to the experiment. Age-matched normoglycemic mice served as controls. Afferent arterioles, intact with the glomeruli, were dissected and microperfused. The effect of luminal application of C-peptide, compared with scrambled C-peptide or vehicle, was investigated. The effect of the Rho-kinase inhibitor Y-27632 was also investigated. Results : C-peptide constricted afferent arterioles in diabetic mice by −27% compared with the control value. Normoglycemic arterioles administered C-peptide displayed a delayed and minute response (−4%). Scrambled C-peptide or vehicle administration, whether administered to hyperglycemic or normoglycemic mice, did not induce any effect. Addition of Y-27632 abolished the effect of C-peptide. Conclusion : C-peptide induces constriction of afferent arterioles in diabetic mice. This can reduce enhanced GFR and may be one of the mechanisms in the renoprotective action of C-peptide in diabetes.
- 1 March 2008
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 294 (3) , R836-R841
Open AccessProinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism
Objective : an increased glomerular filtration rate (GFR) has been postulated as a potential mechanism involved in the progression of diabetic nephropathy. Studies suggest that C-peptide exerts a renoprotective effect on diabetes. The peptide decreases hyperfiltration in patients with type 1 diabetes, as well as in diabetic animal models. In this study, we investigated whether C-peptide causes a change in arteriolar diameter. Research Design and Methods : C57-Bl mice were made diabetic by means of a single intravenous injection of alloxan 2 wk prior to the experiment. Age-matched normoglycemic mice served as controls. Afferent arterioles, intact with the glomeruli, were dissected and microperfused. The effect of luminal application of C-peptide, compared with scrambled C-peptide or vehicle, was investigated. The effect of the Rho-kinase inhibitor Y-27632 was also investigated. Results : C-peptide constricted afferent arterioles in diabetic mice by −27% compared with the control value. Normoglycemic arterioles administered C-peptide displayed a delayed and minute response (−4%). Scrambled C-peptide or vehicle administration, whether administered to hyperglycemic or normoglycemic mice, did not induce any effect. Addition of Y-27632 abolished the effect of C-peptide. Conclusion : C-peptide induces constriction of afferent arterioles in diabetic mice. This can reduce enhanced GFR and may be one of the mechanisms in the renoprotective action of C-peptide in diabetes.
- 28 January 2008
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 24 (2) , 165-168
C‐peptide constricts pancreatic islet arterioles in diabetic, but not normoglycaemic mice
Background: Pancreatic islet blood flow is regulated separately from that of the exocrine pancreas, and a consistent finding during impaired glucose tolerance is an increased blood perfusion. The aim of the present study was to investigate whether C‐peptide affects pancreatic islet arterioles in normal and diabetic mice.Materials and Methods: Control and diabetic C57‐Bl mice were studied after 2 weeks of alloxan‐induced diabetes. Islet arterioles were dissected and microperfused with Dulbecco's modified Eagle medium (DMEM) solution. The effect of luminal application of mouse C‐peptide was investigated.Results: C‐peptide reduced the diameter of islet arterioles from diabetic mice (−10 ± 4%, P < 0.05) compared to base‐line values, whilst arterioles from normoglycaemic animals did not respond to C‐peptide (P = 0.2).Conclusion: These findings suggest a role for C‐peptide in the regulation of islet blood flow, especially during conditions with impaired glucose tolerance. Copyright © 2007 John Wiley & Sons, Ltd.
- 28 January 2008
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 24 (2) , 165-168
C‐peptide constricts pancreatic islet arterioles in diabetic, but not normoglycaemic mice
Background: Pancreatic islet blood flow is regulated separately from that of the exocrine pancreas, and a consistent finding during impaired glucose tolerance is an increased blood perfusion. The aim of the present study was to investigate whether C‐peptide affects pancreatic islet arterioles in normal and diabetic mice.Materials and Methods: Control and diabetic C57‐Bl mice were studied after 2 weeks of alloxan‐induced diabetes. Islet arterioles were dissected and microperfused with Dulbecco's modified Eagle medium (DMEM) solution. The effect of luminal application of mouse C‐peptide was investigated.Results: C‐peptide reduced the diameter of islet arterioles from diabetic mice (−10 ± 4%, P < 0.05) compared to base‐line values, whilst arterioles from normoglycaemic animals did not respond to C‐peptide (P = 0.2).Conclusion: These findings suggest a role for C‐peptide in the regulation of islet blood flow, especially during conditions with impaired glucose tolerance. Copyright © 2007 John Wiley & Sons, Ltd.
- Open Access
- 1 December 2007
- Published by Wiley in Acta Physiologica
- Vol. 191 (4) , 253
Endothelin regulates NOS1 and NOS3 isoforms in the renal medulla
- 1 December 2007
- Published by Wiley in Acta Physiologica
- Vol. 191 (4) , 253
Open AccessEndothelin regulates NOS1 and NOS3 isoforms in the renal medulla
- 1 December 2001
- Published by Wiley in Acta Physiologica Scandinavica
- Vol. 173 (4) , 351-358
Effects of long-term inhibition of neuronal nitric oxide synthase on blood pressure and renin release
- 1 December 2001
- Published by Wiley in Acta Physiologica Scandinavica
- Vol. 173 (4) , 351-358
Effects of long-term inhibition of neuronal nitric oxide synthase on blood pressure and renin release